Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Myocardial salvage in acute myocardial infarction--challenges in clinical translation.

Literature DB >> 21851825

Myocardial salvage in acute myocardial infarction--challenges in clinical translation.

Daria Mochly-Rosen, Kevin V Grimes.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：
Biomarkers

Year: 2011 PMID： 21851825 PMCID： PMC3693548 DOI： 10.1016/j.yjmcc.2011.08.002

Source DB: PubMed Journal: J Mol Cell Cardiol ISSN： 0022-2828 Impact factor: 5.000

× No keyword cloud information.

25 in total

1. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?

Authors: Kwabena Mensah; Mihaela M Mocanu; Derek M Yellon
Journal: J Am Coll Cardiol Date: 2005-04-19 Impact factor: 24.094

2. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.

Authors: Youlan L Gu; Marthe A Kampinga; Wouter G Wieringa; Marieke L Fokkema; Maarten W Nijsten; Hans L Hillege; Ad F M van den Heuvel; Eng-Shiong Tan; Gabija Pundziute; Rik van der Werf; Siyrous Hoseyni Guyomi; Iwan C C van der Horst; Felix Zijlstra; Bart J G L de Smet
Journal: Circulation Date: 2010-11-15 Impact factor: 29.690

3. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

Authors: Allan M Ross; Raymond J Gibbons; Gregg W Stone; Robert A Kloner; R Wayne Alexander
Journal: J Am Coll Cardiol Date: 2005-06-07 Impact factor: 24.094

4. Direct activation of mitochondrial K(ATP) channels mimics preconditioning but protein kinase C activation is less effective in middle-aged rat hearts.

Authors: M Tani; Y Honma; H Hasegawa; K Tamaki
Journal: Cardiovasc Res Date: 2001-01 Impact factor: 10.787

5. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo.

Authors: Koichi Inagaki; Leon Chen; Fumiaki Ikeno; Felix H Lee; Ken-ichi Imahashi; Donna M Bouley; Mehrdad Rezaee; Paul G Yock; Elizabeth Murphy; Daria Mochly-Rosen
Journal: Circulation Date: 2003-11-03 Impact factor: 29.690

6. Protein kinase Cdelta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria.

Authors: Christopher L Murriel; Eric Churchill; Koichi Inagaki; Luke I Szweda; Daria Mochly-Rosen
Journal: J Biol Chem Date: 2004-08-31 Impact factor: 5.157

7. Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator.

Authors: Koichi Inagaki; Harvey S Hahn; Gerald W Dorn; Daria Mochly-Rosen
Journal: Circulation Date: 2003-07-14 Impact factor: 29.690

8. Trends in heart failure incidence and survival in a community-based population.

Authors: Véronique L Roger; Susan A Weston; Margaret M Redfield; Jens P Hellermann-Homan; Jill Killian; Barbara P Yawn; Steven J Jacobsen
Journal: JAMA Date: 2004-07-21 Impact factor: 56.272

9. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.

Authors: Christopher B Granger; Kenneth W Mahaffey; W Douglas Weaver; Pierre Theroux; Judith S Hochman; Thomas G Filloon; Scott Rollins; Thomas G Todaro; Jose C Nicolau; Witold Ruzyllo; Paul W Armstrong
Journal: Circulation Date: 2003-08-18 Impact factor: 29.690

10. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.

Authors: Kenneth W Mahaffey; Christopher B Granger; Jose C Nicolau; Witold Ruzyllo; W Douglas Weaver; Pierre Theroux; Judith S Hochman; Thomas G Filloon; Christopher F Mojcik; Thomas G Todaro; Paul W Armstrong
Journal: Circulation Date: 2003-08-18 Impact factor: 29.690

4 in total